Alterity Therapeutics Ltd has released a press release.
US FDA Approval for IND Application for ATH434 for MSA
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Appendix 4E & Annual Report 2022
- ATH434 Phase 2 clinical launched in Europe
- First Patient dosed in ATH434 Phase 2 Clinical Trial
- Alterity receives a $4.1 million R&D Tax Refund
- Regulatory Approval to Proceed with Phase 2 Trial in Italy
Later from Alterity Therapeutics
- ATH434 Clinical Trial launched in Australia
- New US patent for compounds to treat neurodegeneration
- ATH434 clinical trial launched in the US
- ATH434 Clinical Trial Launched in Italy
- Regulatory approval for Phase II trial in France and Austria
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics